I agree Joel is very overpaid based on the value delivered so far. That said the company is in a good position fundamentally...good to see revenue opportunity in Clarion is unlocked, and I believe we are expecting IHL-42x and 675 readouts this year? IHL-42x also looks good considering it worked in the POC trials.
- Forums
- ASX - By Stock
- IHL
- General discussion
General discussion, page-19215
-
-
- There are more pages in this discussion • 719 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online